David Calhoun to Follow-Up Studies
This is a "connection" page, showing publications David Calhoun has written about Follow-Up Studies.
Connection Strength
0.898
-
Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension. 2020 02; 75(2):510-515.
Score: 0.149
-
Siddiqui M, Judd EK, Dudenbostel T, Zhang B, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. Hypertension. 2019 09; 74(3):652-659.
Score: 0.145
-
Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG, Oparil S, Calhoun DA. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018 08; 72(2):343-349.
Score: 0.134
-
Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
Score: 0.100
-
Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug; 24(8):532-7.
Score: 0.074
-
Czarina Acelajado M, Calhoun DA. Treatment of resistant hypertension. Minerva Cardioangiol. 2009 Dec; 57(6):787-812.
Score: 0.074
-
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
Score: 0.049
-
Parikh V, Thaler E, Kato M, Gillespie MB, Nguyen S, Withrow K, Calhoun D, Soose R, Stevens D, Stevens S, Larsen C, Reddy M, Lakkireddy D. Early feasibility of hypoglossal nerve upper airway stimulator in patients with cardiac implantable electronic devices and continuous positive airway pressure-intolerant severe obstructive sleep apnea. Heart Rhythm. 2018 08; 15(8):1165-1170.
Score: 0.033
-
Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, Yano Y, Viera AJ, Shimbo D. Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Hypertens. 2015 May; 28(5):640-8.
Score: 0.026
-
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
Score: 0.026
-
Diaz KM, Booth JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014 Sep; 64(3):465-71.
Score: 0.025
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
Score: 0.025
-
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
Score: 0.022
-
Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
Score: 0.017